Previous 10 | Next 10 |
BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, Interim CEO, w...
Akcea Therapeutics, Inc. (AKCA) Q4 2019 Earnings Conference Call February 25, 2020 4:30 PM ET Company Participants Kathleen Gallagher - VP of Corporate Communications and IR Damien McDevitt - Interim Chief Executive Officer Mike MacLean - Chief Financial Officer Kyle Jenne -...
Image source: The Motley Fool. Akcea Therapeutics, Inc. (NASDAQ: AKCA) Q4 2019 Earnings Call Feb 25, 2020 , 4:30 p.m. ET Operator Continue reading
The following slide deck was published by Akcea Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Akcea Therapeutics (NASDAQ: AKCA ): Q4 GAAP EPS of $0.86 beats by $0.41 . More news on: Akcea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Reported Full Year 2019 Global Net Product Revenues of $42 Million and Fourth Quarter 2019 Global Net Product Revenues of $14 Million Achieved the 2-2-2 plan: launched two products, initiated two phase 3 programs and reported positive phase 2 data on two pipeline programs ...
Source: Ionis Pharmaceuticals, Inc . | IONS Website Ticker: IONS Current Stock Price (02/16/2020): $60.13 Recommendation: Long Price Target: $71 Company Overview: Ionis Pharmaceuticals, Inc. ( IONS) , founded in 1989 in the USA, is a specialist in discovering and developing ...
BOSTON, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February 25 at 4:30 p.m. Eastern Time to discuss its 2019 financial results and report on...
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman, Ph.D., to the Company’s Board of Directors, expanding the board to 11 members. Dr. Salzman h...
Akcea Therapeutics (NASDAQ: AKCA) and Ionis Pharmaceuticals (NASDAQ: IONS) announced on Tuesday the results for a phase 2 trial featuring AKCEA-ANGPTL3- L Rx , a drug candidate developed to combat hypertriglyceridemia. Patients with non-alcoholic fatty liver disease, type 2 diabetes, and...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...